6533b827fe1ef96bd1286bb7
RESEARCH PRODUCT
Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.
Nadia Rosalia CaccamoSerena MeravigliaGiuseppe CiceroGaspare GulottaFrancesco MoschellaAdriana CordovaEliana GulottaAlfredo SalernoFrancesco Dielisubject
Adjuvants ImmunologicDiphosphonatesCell Line TumorNeoplasmsT-LymphocytesProtein PrenylationAnimalsHumansReceptors Antigen T-Cell gamma-deltaImmunotherapyHuman gamma delta T cells tumors phosphoantigens bisphosphonates immunotherapydescription
BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic protocols based on N-aminobisphosphonate administration and several Phase I-II trials are ongoing investigating the activity of zoledronic acid plus IL-2 in solid tumours.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2008-05-14 | Current medicinal chemistry |